|
Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. |
|
|
Stock and Other Ownership Interests - Salarius Pharmaceuticals |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Churchill Pharmaceuticals; Clovis Oncology; Dendreon; Janssen; Janssen Biotech; Janssen Oncology; Janssen Research & Development; Johnson & Johnson; Pfizer; Roche |
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Research & Development (Inst); Medivation (Inst); OncoGenex (Inst); Sotio; Sotio (Inst); Theraclone Sciences (Inst) |
|
|
Honoraria - Astellas Pharma; Clovis Oncology; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Janssen |
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Janssen; Sanofi |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst) |
|
|
Leadership - Large Urology Group Practice Association |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar |
|
|
|
|
Stock and Other Ownership Interests - CTI (I) |
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Bayer; Blue Earth Diagnostics; Churchill Pharmaceuticals; Clovis Oncology; Dendreon; Emergent BioSolutions; Endocyte; Ferring; Medivation; MorphoSys; Myriad Genetics; Orion; Parexel |
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Asana Biosciences; Astellas Pharma; Bayer; Blue Earth Diagnostics; Churchill Pharmaceuticals; Clovis Oncology; Dendreon; Emergent BioSolutions; Emergent BioSolutions; Endocyte; Ferring; Genentech; Menarini; Myriad Genetics; Orion |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Janssen; Medivation, which was acquired by Pfizer in September 2016; Sanofi |
Research Funding - Astellas Pharma; Bavarian Nordic; Janssen; Medivation, which was acquired by Pfizer in September 2016 |
|
|
Honoraria - Astellas Pharma; Janssen |
Consulting or Advisory Role - Astellas Pharma; Bayer; ESSA; Genentech; Janssen; Orion; Sanofi |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Ferring; GlaxoSmithKline; Janssen-Cilag; Merck; Novartis; Pfizer; Roche |
Research Funding - Novartis |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi; Takeda |
Consulting or Advisory Role - Astellas Pharma; Bayer; Johnson & Johnson |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Pfizer; Sanofi; Takeda |
Research Funding - Astellas Pharma; Bayer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
|
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda |
Speakers' Bureau - Amgen; Janssen |
Research Funding - Ferring (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |